PHARMACOLOGICAL STRATEGIES FOR OPTIMIZING ANTIBIOTIC THERAPY IN THE ERA OF ANTIMICROBIAL RESISTANCE: INTEGRATING PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTIMICROBIAL STEWARDSHIP

Authors

  • Khotamova Gulnoza Komilovna Asian International University , https://orcid.org/0009-0000-2690-1500

Keywords:

antimicrobial resistance, antibiotics, pharmacology, pharmacokinetics, pharmacodynamics, antimicrobial stewardship, AWaRe, rational pharmacotherapy, de-escalation, microbiological diagnostics.

Abstract

Background. Antimicrobial resistance is a major challenge to contemporary clinical medicine and threatens the effectiveness of antibacterial therapy across multiple fields, including intensive care, surgery, oncology, transplantation, and neonatology. Inappropriate prescribing, excessive use of broad-spectrum antibiotics, inadequate dosing, unnecessarily prolonged treatment, and insufficient use of microbiological diagnostics contribute to the selection and spread of resistant microorganisms.

Objective. The aim of this review was to analyze the principal pharmacological strategies for optimizing antibiotic therapy under conditions of increasing antimicrobial resistance, with particular emphasis on pharmacokinetic/pharmacodynamic principles, microbiological guidance, de-escalation, the WHO AWaRe framework, and antimicrobial stewardship.

Materials and Methods. A narrative analytical review was conducted using recommendations of the World Health Organization, the WHO AWaRe Antibiotic Book, guidance from the U.S. Centers for Disease Control and Prevention, and relevant pharmacological and clinical literature. The analysis focused on antibiotic selection, pharmacokinetic and pharmacodynamic targets, route of administration, dose individualization, microbiological diagnostics, adverse effects, duration of treatment, reassessment of therapy, and stewardship interventions.

Results. Rational antibiotic therapy requires integration of pathogen-related, drug-related, and patient-related factors. The probability of bacterial infection, site of infection, expected pathogens, local resistance patterns, antimicrobial susceptibility, tissue penetration, renal and hepatic function, drug interactions, adverse effects, and pharmacokinetic/pharmacodynamic targets should all be considered. Early empirical therapy may be necessary in severe infection, but it should be reassessed when microbiological and clinical data become available. De-escalation, appropriate treatment duration, and avoidance of unnecessary broad-spectrum exposure are important strategies for reducing selective pressure.

Conclusion. Optimization of antibacterial pharmacotherapy should combine evidence-based clinical decision-making, pharmacokinetic/pharmacodynamic principles, microbiological diagnostics, individualized dosing, and structured antimicrobial stewardship. This approach can improve therapeutic effectiveness and safety while contributing to preservation of antibiotic activity at the population level.

 

References

1.World Health Organization. The WHO AWaRe (Access, Watch, Reserve) Antibiotic Book. Geneva: World Health Organization; 2022.

2.World Health Organization. WHO AWaRe System for Antimicrobial Stewardship. Geneva: WHO; 2025.

3.Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta: CDC; updated September 15, 2025.

4.Centers for Disease Control and Prevention. Core Elements of Antibiotic Stewardship. Atlanta: CDC; updated September 10, 2025.

5.Centers for Disease Control and Prevention. Priorities for Hospital Core Element Implementation. Atlanta: CDC; updated March 18, 2024.

6.Centers for Disease Control and Prevention. Core Elements of Outpatient Antibiotic Stewardship. Atlanta: CDC; updated August 3, 2026.

7.Sharland M, Cappello B, Ombajo LA, et al. The WHO AWaRe Antibiotic Book: providing guidance on optimal use and informing policy. Lancet Infect Dis. 2022;22(11):1528–1530. doi:10.1016/S1473-3099(22)00683-1.

8.Centers for Disease Control and Prevention. The Core Elements of Hospital Antibiotic Stewardship Programs: 2019. Atlanta: U.S. Department of Health and Human Services; 2019.

9.World Health Organization. Global Action Plan on Antimicrobial Resistance. Geneva: WHO.

10.World Health Organization. Antimicrobial Stewardship Programmes in Health-Care Facilities in Low- and Middle-Income Countries. Geneva: WHO.

11.Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis.

12.Tamma PD, Miller MA, Cosgrove SE. Rethinking how antibiotics are prescribed: incorporating the 4 moments of antibiotic decision making into clinical practice. JAMA.

13.Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. Mayo Clin Proc.

14.Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw-Hill.

15.Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. New York: McGraw-Hill.

16.Rang HP, Dale MM, Ritter JM, Flower RJ, Henderson G. Rang & Dale’s Pharmacology. Elsevier.

Published

2026-09-23